Drugs / RG-7841
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02092792 | Apr 2014 → Jul 2017 | neoplasm | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG-7841 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297935 ↗ |
| Known as | Anti-ly6e-vcmmae | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297935 ↗ |
| Known as | DLYE5953A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02092792 ↗ |
| Target | LY6E | “Lymphocyte antigen 6E binding agent” CHEMBL4297935 ↗ |